このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cerus 将来の成長

Future 基準チェック /16

Cerusは、46.3%と10%でそれぞれ年率46.3%で利益と収益が成長すると予測される一方、EPSはgrowで61.3%年率。

主要情報

46.3%

収益成長率

61.3%

EPS成長率

Medical Equipment 収益成長	16.6%
収益成長率	10.0%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	08 May 2024

今後の成長に関する最新情報

The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 05

Recent updates

The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

May 05

Here's Why Cerus (NASDAQ:CERS) Can Afford Some Debt

Apr 12

Cerus Corporation (NASDAQ:CERS) Stock Rockets 29% But Many Are Still Ignoring The Company

Mar 07

Slammed 29% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

Jan 18

Health Check: How Prudently Does Cerus (NASDAQ:CERS) Use Debt?

Oct 06

Is Cerus (NASDAQ:CERS) A Risky Investment?

Jul 07

Slammed 32% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

May 12

Cerus: Technical Support Fades, Investment Case Weakens (Technical Analysis)

Sep 29

Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M

Aug 04

Cerus: Lacks Conviction Against Macro Backdrop, Technicals Supportive Of Near-Term Upside

Jul 14

業績と収益の成長予測

NasdaqGM:CERS - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	219	N/A	N/A	N/A	1
12/31/2025	193	-13	N/A	N/A	4
12/31/2024	174	-26	N/A	N/A	4
3/31/2024	164	-32	-37	-33	N/A
12/31/2023	156	-37	-48	-43	N/A
9/30/2023	154	-50	-36	-30	N/A
6/30/2023	153	-51	-25	-21	N/A
3/31/2023	156	-46	-16	-13	N/A
12/31/2022	162	-43	-28	-26	N/A
9/30/2022	158	-38	-26	-25	N/A
6/30/2022	154	-42	-30	-30	N/A
3/31/2022	145	-49	-39	-38	N/A
12/31/2021	131	-54	-35	-34	N/A
9/30/2021	119	-60	-43	-42	N/A
6/30/2021	107	-61	-41	-40	N/A
3/31/2021	97	-61	-41	-39	N/A
12/31/2020	92	-60	-43	-42	N/A
9/30/2020	85	-62	-43	-41	N/A
6/30/2020	79	-66	-62	-58	N/A
3/31/2020	76	-69	-70	-63	N/A
12/31/2019	75	-71	-74	-65	N/A
9/30/2019	70	-71	-73	-64	N/A
6/30/2019	68	-67	-55	-47	N/A
3/31/2019	65	-62	-48	-43	N/A
12/31/2018	61	-58	-32	-31	N/A
9/30/2018	61	-53	-35	-34	N/A
6/30/2018	56	-52	-42	-42	N/A
3/31/2018	50	-56	-46	-46	N/A
12/31/2017	44	-61	N/A	-52	N/A
9/30/2017	37	-63	N/A	-52	N/A
6/30/2017	37	-64	N/A	-55	N/A
3/31/2017	37	-65	N/A	-57	N/A
12/31/2016	37	-63	N/A	-54	N/A
9/30/2016	37	-64	N/A	-53	N/A
6/30/2016	35	-65	N/A	-48	N/A
3/31/2016	34	-63	N/A	-48	N/A
12/31/2015	34	-56	N/A	-51	N/A
9/30/2015	34	-61	N/A	-51	N/A
6/30/2015	36	-56	N/A	-51	N/A
3/31/2015	36	-48	N/A	-46	N/A
12/31/2014	36	-39	N/A	-40	N/A
9/30/2014	36	-24	N/A	-38	N/A
6/30/2014	36	-34	N/A	-32	N/A
3/31/2014	38	-33	N/A	-28	N/A
12/31/2013	40	-43	N/A	-27	N/A
9/30/2013	41	-39	N/A	-23	N/A
6/30/2013	39	-22	N/A	-19	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CERS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CERS今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CERS今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CERSの収益 ( 10% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: CERSの収益 ( 10% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CERSの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Cerus 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Consensus EPS estimates fall by 29%

The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Cerus Corporation Reiterates Earnings Guidance for the Year Ending December 31, 2024

Consensus EPS estimates fall by 24%, revenue upgraded

Consensus EPS estimates upgraded to US$0.085 loss, revenue downgraded

No longer forecast to breakeven

Recent updates

Consensus EPS estimates fall by 29%

The Cerus Corporation (NASDAQ:CERS) First-Quarter Results Are Out And Analysts Have Published New Forecasts

First quarter 2024 earnings: EPS misses analyst expectations

Cerus Corporation Reiterates Earnings Guidance for the Year Ending December 31, 2024

Cerus Corporation, Annual General Meeting, Jun 05, 2024

Cerus Corporation to Report Q1, 2024 Results on May 02, 2024

Here's Why Cerus (NASDAQ:CERS) Can Afford Some Debt

Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets - Doubling Previous Shelf Life

Consensus EPS estimates fall by 24%, revenue upgraded

Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients

Consensus EPS estimates upgraded to US$0.085 loss, revenue downgraded

Chief Medical Officer notifies of intention to sell stock

No longer forecast to breakeven

Cerus Corporation (NASDAQ:CERS) Stock Rockets 29% But Many Are Still Ignoring The Company

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Reiterates Product Revenue Guidance for the Full Year 2024

Cerus Corporation to Report Fiscal Year 2023 Results on Mar 05, 2024

Forecast to breakeven in 2025

Slammed 29% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

Cerus Corporation Provides Revenue Guidance for the Fiscal Year 2024

Price target decreased by 28% to US$4.13

Cerus Corporation has filed a Follow-on Equity Offering in the amount of $96.8 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Provides Product Revenue Guidance for the Full-Year 2023

Cerus Corporation to Report Q3, 2023 Results on Nov 02, 2023

Health Check: How Prudently Does Cerus (NASDAQ:CERS) Use Debt?

Cerus Corporation Announces the Appointment of Alicia Goodman as Chief Human Resources Officer

Price target decreased by 25% to US$5.75

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Cerus Corporation Revises Revenue Guidance for the Year 2023

New minor risk - Share price stability

Is Cerus (NASDAQ:CERS) A Risky Investment?

Slammed 32% Cerus Corporation (NASDAQ:CERS) Screens Well Here But There Might Be A Catch

Consensus EPS estimates fall by 12%

No longer forecast to breakeven

Cerus Corporation Reiterates Revenue Guidance for the Year 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Medical Officer exercised options and sold US$71k worth of stock

No longer forecast to breakeven

Cerus Corporation to Report Q4, 2022 Results on Feb 28, 2023

No longer forecast to breakeven

Cerus Corporation Provides Revenue Guidance for the Full Year 2023

Independent Director exercised options to buy US$94k worth of stock.

Price target decreased to US$8.70

No longer forecast to breakeven

Price target decreased to US$8.70

Consensus estimates of losses per share improve by 13%

Price target decreased to US$8.50

Third quarter 2022 earnings released: US$0.048 loss per share (vs US$0.072 loss in 3Q 2021)

Cerus Corporation Revises Revenue Guidance for Full Year 2022

Price target decreased to US$8.50

Cerus Corporation Announces Health Canada Approval for Intercept Blood System for Platelets with Seven-Day Storage

Cerus Corporation to Report Q3, 2022 Results on Nov 03, 2022

Cerus: Technical Support Fades, Investment Case Weakens (Technical Analysis)

Chief Medical Officer notifies of intention to sell stock

Consensus forecasts updated

No longer forecast to breakeven

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Reiterates Revenue Guidance for the Full Year 2022

Cerus GAAP EPS of -$0.05 beats by $0.02, revenue of $47.63M beats by $4.87M

Cerus Corporation to Report Q2, 2022 Results on Aug 04, 2022

Cerus: Lacks Conviction Against Macro Backdrop, Technicals Supportive Of Near-Term Upside

Cerus Corporation Appoints Hua Shan to its Board of Directors

Is Cerus (NASDAQ:CERS) Using Debt In A Risky Way?

VP of Finance & CFO notifies of intention to sell stock

Price target decreased to US$9.40

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cerus Corporation Revises Product Revenue Guidance for the Full Year of 2022